Miyano Takuya, Hirouchi Masakazu, Yoshimura Naoki, Hattori Kotaro, Mikkaichi Tsuyoshi, Kiyosawa Naoki
Translational Science Department II, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa, Tokyo 140-8710, Japan.
Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
Int J Mol Sci. 2024 Dec 17;25(24):13522. doi: 10.3390/ijms252413522.
Schizophrenia is a complex and heterogenous psychiatric disorder characterized by positive, negative, and cognitive symptoms. Our previous study identified three subgroups of schizophrenia patients based on plasma microRNA (miRNA) profiles. The present study aims to (1) verify the reproducibility of the miRNA-based patient stratification and (2) explore the pathophysiological pathways linked to the symptoms using plasma miRNAs. We measured levels of 376 miRNAs in plasma samples of schizophrenia patients and obtained their Positive and Negative Syndrome Scale (PANSS) scores and the Brief Assessment of Cognition in Schizophrenia (BACS) scores. The plasma miRNA profiles identified similar subgroups of patients as in the previous study, suggesting miRNA-based patient stratification is potentially reproducible. Our multivariate analysis identified optimal combinations of miRNAs to estimate the PANSS positive and negative subscales and BACS composite scores. Those miRNAs consistently enriched 'inflammation' and 'NFκB1' according to miRNA set enrichment analysis. Our literature-based text mining and survey confirmed that those miRNAs were associated with IL-1β, IL-6, and TNFα, suggesting that exacerbated positive, negative, and cognitive symptoms are associated with high inflammation. In conclusion, miRNAs are a potential biomarker to identify patient subgroups reflecting pathophysiological conditions and to investigate symptom-related molecular mechanisms in schizophrenia.
精神分裂症是一种复杂的异质性精神障碍,其特征为阳性、阴性和认知症状。我们之前的研究基于血浆微小RNA(miRNA)谱鉴定出了精神分裂症患者的三个亚组。本研究旨在(1)验证基于miRNA的患者分层的可重复性,以及(2)使用血浆miRNAs探索与症状相关的病理生理途径。我们测量了精神分裂症患者血浆样本中376种miRNAs的水平,并获得了他们的阳性和阴性症状量表(PANSS)评分以及精神分裂症认知简短评估(BACS)评分。血浆miRNA谱鉴定出了与之前研究中相似的患者亚组,这表明基于miRNA的患者分层可能具有可重复性。我们的多变量分析确定了用于估计PANSS阳性和阴性分量表以及BACS综合评分的miRNAs的最佳组合。根据miRNA集富集分析,这些miRNAs一致地富集了“炎症”和“NFκB1”。我们基于文献的文本挖掘和调查证实,这些miRNAs与白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNFα)相关,这表明阳性、阴性和认知症状的加重与高度炎症有关。总之,miRNAs是一种潜在的生物标志物,可用于识别反映病理生理状况的患者亚组,并研究精神分裂症中与症状相关的分子机制。